Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. (CELZ) filed this Form 8-K on December 3, 2021, reporting events occurring on December 2 and December 7, 2021. The Company is a Nevada corporation focused on regenerative medicine therapies. Key events include a public equity offering, a transfer of listing to The NASDAQ Capital Market, and significant changes to the Board of Directors.
Key Financial Metrics and Capital Structure
- Gross Proceeds: $16,003,750 from the sale of 3,875,000 shares of Common Stock and accompanying warrants.
- Offering Price: $4.13 per share (combined price for Common Stock and Warrant).
- Warrant Terms: Warrants to purchase 3,875,000 shares at an exercise price of $4.13 per share.
- Over-Allotment Option: Underwriter granted a 45-day option to purchase up to 581,250 additional shares and/or warrants.
- Underwriter Warrants: 348,750 warrants issued to the underwriter (4.5% of offering) exercisable at $5.1625 per share.
- Estimated Expenses: Approximately $1,500,000, including a 7% underwriting discount and commissions.
- Debt Obligations: Outstanding 15% Original Issue Discount Senior Notes due February 11, 2022, totaling $5,146,176.
Material Changes and Strategic Actions
The Company executed a material definitive agreement to raise capital and restructure its capital base. Proceeds are designated to redeem $5,146,176 of senior notes and repurchase approximately $195,000 of Series A Preferred Stock held by the CEO. Additionally, the Company's Common Stock began trading on The NASDAQ Capital Market under the symbol "CELZ," transitioning from the OTC Pink Market. The Board of Directors was reconstituted with the resignation of Drs. Thomas Ichim and Amit Patel and the appointment of Michael H. Finger, Susan Snow, and Bruce S. Urdang.
Outlook, Risks, and Management Commentary
Management intends to utilize net proceeds for clinical development and commercialization efforts, specifically:
- Conducting a 100-patient clinical study for the StemSpine Regenerative Stem Cell Procedure.
- Initiating a Phase I clinical trial for stroke treatment using ImmCelz technology.
- Hiring marketing and sales personnel for CaverStem and FemCelz products.
- Funding general working capital.
Lock-Up Agreements: Existing stockholders, directors, and officers are subject to 180-day lock-up agreements prohibiting the sale of securities. The Company is also restricted from issuing new common stock or equivalents for 180 days, with limited exceptions.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% underwriting discount and estimated $1.5M in expenses.
- Confirm the successful redemption of the $5.15M Senior Notes due February 2022 to assess immediate debt reduction.
- Review the final prospectus (File No. 333-259834) for detailed risk factors regarding the clinical trials mentioned.
- Monitor the exercise of the 45-day over-allotment option by the underwriter.
- Check the composition of the new Board of Directors and their specific expertise relative to the Company's clinical pipeline.